Short Duration Levetiracetam to Extended Course for Seizure Prophylaxis After aSAH (DOPAST)

The Washington University

Status: Completed

Conditions: Subarachnoid Hemorrhage

Treatments: Other: Brief LEV; Other: Extended LEV

Study type: Interventional

Funder types: Other

Identifiers

NCT01137110

09-1717

Details and patient eligibility

About

Our primary objective is to compare two treatment options for prevention of seizures following a subarachnoid hemorrhage and determine if a short-course regimen of levetiracetam is as efficacious in the prevention of in-hospital seizures when compared to an extended course.

Full description

This is a prospective, single-center, randomized, controlled trial. Patients admitted with spontaneous SAH (and meet enrollment criteria) will be randomized to either levetiracetam 1000 mg twice daily for 3 days or levetiracetam 1000mg twice daily until hospital discharge.

Enrollment: 84 patients

Sex: All

Ages: 18 to 99 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Age >18 years of age
2. Diagnosis of spontaneous SAH

Exclusion criteria

1. SAH secondary to trauma or arteriovenous malformation
2. Early death (defined as death within 3 days of presentation)
3. Known allergy to levetiracetam
4. Know seizure history on chronic AEDs
5. Pregnancy
6. Current incarceration

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

84 participants in 2 patient groups

Brief LEV

Other group

Description:

Administration of three days of levetiracetam twice daily after SAH

Treatment:

Other: Brief LEV

Extended LEV

Other group

Description:

Administration of levetiracetam twice daily after SAH

Treatment:

Other: Extended LEV